ACCEL Subscription

ACCEL Was There: ESC - LoDoCo2 Low-Dose Colchicine in Coronary Disease
Stefan Mark Nidorf, MD, Cardiologist, GenesisCare, Perth, Western Australia

Interviewer: Harriette Van Spall, MD, MPH, FRCPC, Associate Professor of Medicine, Department of Medicine, Division of Cardiology, Department of Health Research Methods, Evidence, and Impact, McMaster University, and Scientist at the Population Health Research Institute, Hamilton, ON

This segment examines strong evidence that supports repurposing colchicine for routine secondary prevention in patients with chronic coronary disease.

Just in Time From JACC: Characteristics of Heart Failure Trials Associated with Under-representation of Women as Lead Author
Harriette Van Spall, MD, MPH, FRCPC, Associate Professor of Medicine, Department of Medicine, Division of Cardiology, Department of Health Research Methods, Evidence, and Impact, McMaster University, and Scientist at the Population Health Research Institute, Hamilton, ON

Interviewer: Laxmi Mehta, MD, FACC, Professor of Medicine, Director of Preventative Cardiology and Women's Cardiovascular Health, The Ohio State University, Columbus, OH

This breaking article assesses trends in clinical trial leadership by women over time, and trial characteristics that are associated with under-representation of women in lead authorship roles.

Time Course of LDL Cholesterol Exposure and Cardiovascular Risks
Michael J. Domanski, MD, FACC, Professor of Medicine, University of Maryland School of Medicine, Baltimore, MD

Interviewer: Alison L. Bailey, MD, FACC, FAACVPR, Chief of Cardiology, Centennial Heart at Parkridge HCA Healthcare, Chattanooga, TN

This paper shows that risks of suboptimal cholesterol control present as early as late adolescence and remain until later in life, underscoring the need for achieving good cholesterol control before adulthood.

VOYAGER PAD and Concomitant Coronary Artery Disease
William R. Hiatt, MD, Professor of Medicine, University of Colorado School of Medicine, Division of Cardiology and CPC Clinical Research, Aurora, CO

Interviewer: Sidney C. Smith Jr., MD, MACC Professor of Medicine/Cardiology, University of North Carolina at Chapel Hill, Chapel Hill, NC
Correspondent: Anthony J. Mazzella MD, Fellow in Training, University of North Carolina, Chapel Hill, NC

Patients with peripheral artery disease (PAD) in the legs are at increased risk for cardiovascular events, particularly after lower extremity revascularization. Concomitant coronary artery disease (CAD) substantially increases cardiac risk in these patients. Rivaroxaban was effective in reducing cardiovascular events in patients with PAD with and without CAD. However, a larger absolute benefit was observed in patients with PAD and CAD, indicating the need to treat fewer patients to prevent one event, compared to patients with PAD without CAD.

EVAPORATE: The Final Results
Matthew J. Budoff, MD, FACC, Professor of Medicine, Lundquist Institute at Harbor-UCLA Medical Center, Torrance, CA

Interviewer: Vinod H. Thourani, MD, FACC, Marcus Chief of Cardiovascular Surgery, Marcus Heart Valve Center and Piedmont Heart Institute, Atlanta, GA
Correspondent: Poonam Velagapudi, MD, MS, FACC, Assistant Professor of Medicine, University of Nebraska Medical Center, Omaha, NE

This groundbreaking study’s data, now being released for the first time, demonstrate plaque regression in response to icosapent ethyl.

New Treatments for an Old Disease: SGLT2i in Heart Failure
Javed Butler, MBBS, MPH, MBA, FACC, Professor and Chair, Department of Medicine, University of Mississippi Medical Center, Jackson, MS

Interviewer: Alison L. Bailey, MD, FACC, FAACVPR, Chief of Cardiology, Centennial Heart at Parkridge HCA Healthcare, Chattanooga, TN

Patients with HF have a high risk of adverse outcomes and need novel therapies beyond the current standard of care. EMPEROR REDUCED looked at higher-risk HFrEF patients (with lower EF and high NT-proBNP) to assess the benefits of SGLT2 inhibition.

EMPEROR REDUCED showed a reduction in the primary outcome with the SGLT2 inhibitor empagliflozin in patients with HF with or without diabetes mellitus.